Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06525298 · ClinicalTrials.gov registry record · Phase 1

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency, sponsored by Eisbach Bio.

Recruiting
Registry status
Phase 1
Development phase
144
Enrollment target
1
Study location

NCT06525298 is a Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency that is actively recruiting participants, run by Eisbach Bio. The registered enrollment target is 144 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06525298, a Phase 1 study of Advanced Solid Tumor and Homologous Recombination Deficiency, is actively recruiting participants, sponsored by Eisbach Bio.

RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
1
Study location

Study Summary

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Conditions Studied

Advanced Solid Tumor Homologous Recombination Deficiency HRR Deficiency

Interventions

  • DRUG Olaparib
  • DRUG Trastuzumab deruxtecan
  • DRUG EIS-12656

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-09-09
Est. Completion 2027-12
Phase Phase 1

Sponsor

Eisbach Bio

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06525298

The ClinicalTrials.gov registry entry for NCT06525298 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% lower). The listed sponsor is Eisbach Bio, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.

NCT06525298 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06525298 about?

NCT06525298 is a clinical study titled "EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors". This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

What is the current status of trial NCT06525298?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-09-09. Estimated completion is 2027-12.

What conditions does trial NCT06525298 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency.

What interventions are being tested in trial NCT06525298?

The interventions under investigation include: Olaparib (DRUG), Trastuzumab deruxtecan (DRUG), EIS-12656 (DRUG).

Who is sponsoring clinical trial NCT06525298?

This trial is sponsored by Eisbach Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06525298 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Homologous Recombination Deficiency

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.